Markets:

Overview

News

Currencies

International

Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

27.70 -0.17 (-0.59%)

Streaming Delayed Price Updated: 10:59 AM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shareholder Notice: Investigation over Possible Breaches of Fiduciary Duties ↗

September 29, 2023

San Diego, CA -- (SBWIRE) -- 09/29/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Travere Therapeutics, Inc.

Via SBWire

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

September 26, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Expert Ratings for Travere Therapeutics ↗

September 22, 2023

Via Benzinga

Micron Technology To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Friday ↗

September 22, 2023

Loop Capital increased the price target for Splunk Inc. (NASDAQ: SPLK) from $135 to $157. Loop Capital analyst Yun Kim downgraded the stock from Buy to Hold. Splunk shares fell 0.1% to $144.25 in...

Via Benzinga

Analyst Ratings for Travere Therapeutics ↗

September 06, 2023

Via Benzinga

The Latest Analyst Ratings for Travere Therapeutics ↗

August 18, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023 ↗

September 22, 2023

Via Benzinga

Back To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challenges ↗

September 21, 2023

William Blair downgraded Travere Therapeutics Inc (NASDAQ: TVTX)

Via Benzinga

Dow Tumbles 200 Points; Darden Restaurants Posts Upbeat Profit ↗

September 21, 2023

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 200 points on Thursday. The Dow traded down 0.58% to 34,239.48 while the NASDAQ fell 1.20% to 13,307.77. The S&P...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 21, 2023

Via Benzinga

Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

September 21, 2023

Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday.

Via Benzinga

Why Shares of Travere Therapeutics Are Slumping Thursday ↗

September 21, 2023

A mixed trial could hurt a kidney drug's chances of full approval.

Via The Motley Fool

Why Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Low ↗

September 21, 2023

It's now up to the FDA whether the company's key drug remains on the market.

Via Investor's Business Daily

Stocks That Hit 52-Week Lows On Thursday ↗

September 21, 2023

During the session on Thursday, 461 stocks hit new 52-week lows.

Via Benzinga

Gold Down Over 1%; FedEx Shares Rise On Earnings Beat ↗

September 21, 2023

U.S. stocks traded lower midway through trading, with the Dow Jones falling around 150 points on Thursday. The Dow traded down 0.46% to 34,284.15 while the NASDAQ fell 1.05% to 13,327.80. The S&P 500...

Via Benzinga

Topics Stocks

Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected ↗

September 21, 2023

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.56% to 34,248.45 while the NASDAQ fell...

Via Benzinga

Topics Stocks

Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today? ↗

September 21, 2023

Travere Therapeutics Inc (NASDAQ: TVTX) announced

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 21, 2023

Via Benzinga

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

September 21, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Broadcom, KB Home And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

September 21, 2023

U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Evercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To Know ↗

September 19, 2023

Via Benzinga

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 11, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug ↗

September 08, 2023

Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way.

Via Benzinga

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

September 05, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

September 05, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference

August 31, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

August 24, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 14, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

NASDAQ: TVTX Investor Notice: Investigation Concerning Potential Securities Laws Violations by Travere Therapeutics, Inc. ↗

August 10, 2023

San Diego, CA -- (SBWIRE) -- 08/10/2023 -- Travere Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Travere Therapeutics Reports Second Quarter 2023 Financial Results

August 03, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.